16 December 2024 in Prenatal Diagnosis
Objective: Congenital diaphragmatic hernia (CDH) is a rare abnormality with highly heterogeneous genetic causes. This study investigated chromosomal and monogenic abnormalities in fetal CDH patients and evaluated the efficacy of chromosomal microarray analysis (CMA) and whole‐exome sequencing (WES) for genetic diagnosis. The clinical features of the patients were also evaluated. Methods: We evaluated the genetic and clinical data of 51 prenatally diagnosed fetuses with CDH. CMA was performed for every patient. If CMA did not yield diagnostic results, the samples were subjected to WES. Results: Compared with fetuses with isolated CDH ( n = 42), those with non‐isolated CDH ( n = 9) presented a higher genetic diagnostic rate (22.2% vs. 2.4%). The overall diagnostic yield was 5.9%, comprising 3.9% from chromosomal microarray analysis (CMA) and an additional 2.0% from whole exome sequencing (WES). CMA identified (1) mosaic trisomy 18 in a patient with isolated CDH; and (2) 4q terminal deletion syndrome in a patient with non‐isolated CDH. WES identified a novel missense mutation, PLS3 c.1763A > G , associated with X‐linked CDH in a patient with non‐isolated CDH and a family history of recurrent CDH. Conclusion: Genetic testing should be offered for all fetuses with CDH, regardless of whether the cases are isolated or non‐isolated. WES should be considered if CMA fails to provide a diagnostic result, particularly in patients with non‐isolated CDH and a family history of recurrent CDH.
1 October 2025 in Genetics in Medicine
Secondary findings (SFs) identified through genomic sequencing are results unrelated to the primary indication but with potential clinical utility. Although genomic technologies are increasingly used in perinatal diagnosis, the clinical implications of SFs remain insufficiently explored. We evaluated the detection rates, phenotypic concordance, and clinical implications of SFs in a prenatal cohort undergoing trio exome sequencing (trio-ES). This was a single-center cohort study of 424 consecutive families who underwent prenatal trio-ES at a tertiary maternal-fetal medicine center from January 2019 to December 2023. SFs were classified using a 3-category framework (medically actionable risks, childhood-onset diseases, and carrier status) and analyzed via a stepwise protocol, including validation by a specialized clinical review panel. Among 1272 individuals, SFs were identified in 2.9% (37/1272), including 2.1% of fetuses (9/424) and 3.3% of parents (28/848). SF-related phenotypes were observed in 1 fetus and 3 adults. SFs prompted medical management changes in 27.0% (10/37) of cases, including 1 pregnancy termination, 7 adults initiating medical evaluations, and 2 couples committing to prenatal diagnosis/neonatal screening in subsequent pregnancies. Systematic SF reporting in prenatal diagnosis has demonstrated clinical value by facilitating pregnancy decisions, informing parental health risks, and enabling preventive reproductive strategies.
18 July 2025 in Prenatal Diagnosis
Objective: Expanded carrier screening (ECS) is used to assess the reproductive probability of having an offspring affected by an autosomal recessive or X‐linked recessive genetic disorder. Rarely, a presumably healthy individual may be identified to carry variants that could influence their health. This study aimed to investigate the incidence of potentially affected individuals, with the objective of improving counseling for ECS.Methods: A retrospective study of a cohort of 3001 individuals who sought ECS during early pregnancy or preconception was conducted. Potentially affected individuals carrying biallelic pathogenic variants for autosomal recessive diseases, as well as females carrying a heterozygous pathogenic variant for X‐linked disease, were identified.Results: A total of 13 potentially affected individuals (0.43%) were identified; 5 patients were homozygous or compound heterozygous for autosomal recessive diseases, and 8 were heterozygous for X‐linked diseases. The majority of the potentially affected individuals were asymptomatic (85%, 11/13) at the time of assessment. Only two patients exhibited mild clinical manifestations.Conclusion: People who intend to undergo ECS should be informed that they themselves may be identified as potentially affected individuals for whom clinical evaluation and surveillance are recommended.
7 September 2026 in Clinics
18 March 2026 in Journal of Medical Screening
Objectives: To evaluate the efficacy of non-invasive prenatal testing in detecting sex chromosome aneuploidies. Methods: A total of 67,099 pregnant women were recruited in this retrospective observational study at Peking Union Medical College Hospital; 300 cases at high risk of sex chromosome aneuploidies were screened and 36 cases refused invasive prenatal diagnosis after detailed prenatal genetic counselling. The clinical data and prenatal diagnosis results were collected. Results: 101 cases were in accordance with non-invasive prenatal testing results after invasive prenatal diagnosis: 95 cases had follow-up confirmation with abnormal sex aneuploidies (14 for monosomy X; 36 for 47, XXY; 22 for trisomy X and 23 for 47, XYY). The total positive predictive value was 38.26% (101/264). The accuracy of different Z scores was calculated, respectively, with positive predictive value ranging from 33.96% to 41.38% and a decreased sensitivity with rise of the Z score. Conclusions: Non-invasive prenatal testing is an effective screening method for sex chromosome trisomy, rather than monosomy X, with relatively high accuracy. Z score = 3 is an optimum risk threshold in sex chromosome aneuploidies.
9 July 2026 in Prenatal Diagnosis
Objective: To develop a customized expanded carrier screening (ECS) solution for 8271 variants of 265 genes. Based on a microarray platform, this solution demonstrates comparable accuracy to next‐generation sequencing (NGS) platform; however, it has a lower cost, a faster speed, and a simplified data—analysis process. Method: A dedicated panel composed of 8271 variants of 265 high—priority genes was developed for custom microarray fabrication. To test the performance of the custom microarray, we selected 1051 blood samples from an NGS‐based ECS project to conduct a blind test. The evaluation indicators include sensitivity, specificity and positive predictive value. Results: 582 variants were identified in 69 genes. The concordance between the microarray platform and NGS platform results reaches 99.5%. The microarray demonstrated high sensitivity (99.8%) and specificity (99.8%), showing excellent performance in both positive and negative samples. The microarray platform reduces testing cycles to 3–4 days and lowers costs by 94%–96%. Conclusion: This study confirms that microarray‐based carrier screening is a reliable, cost‐effective, and timely alternative to NGS, and it is especially suitable for large‐scale population screening.